Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician

LEARNING OBJECTIVES
At the end of the activity, participants will be able to:
• Identify the risks of kidney disease and their consequences in patients with T2DM.
• Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2DM and CKD.
• Become familiar with the mineralocorticoid receptor antagonist and endothelin receptor antagonist under latephase investigation.

Chronic kidney disease (CKD) is defined as ≥1 abnormalities of kidney structure or function that have been present
for >3 months and have health implications.
Markers of kidney damage include albuminuria (urine albumin excretion
rate ≥30 mg/24 hours or urine albumin-to-creatinine ratio [UACR] ≥30 mg/g), urine sediment abnormalities, electrolyte and other abnormalities caused by tubular disorders,
abnormalities detected by histology, structural abnormalities detected by imaging, or history of kidney transplantation.
Decreased kidney function is indicated by an estimated glomerular filtration rate (eGFR)